Data Show Fosrenol Has Greater Phosphate Binding Affinity Than Sevelamer HCl
Data presented at the National Kidney Foundation 2005 clinical meeting in Washington, D.C., showed that, in vitro, Fosrenol binds phosphate across a broad pH range with higher affinity than sevelamer HCl.
Fosrenol (lanthanum carbonate) is marketed by Shire Pharmaceuticals Group. The phosphate-binding affinity of Fosrenol was more than 200 times higher compared to sevelamer HCl at pH 3, which simulates the acidic environment of the stomach. When assessed at pH 5 to 7, the affinity of Fosrenol was four-fold higher compared to sevelamer HCl.
In addition, the presence of bile acids did not affect the stability of the Fosrenol/phosphate complex, whereas bile acids led to a more than 20-fold reduction in phosphate-binding affinity of sevelamer HCl with the consequent release of its phosphate. The clinical relevance of the effect of pH on in vitro binding of Fosrenol has not been established.
Upcoming Events
-
21Oct